Artwork

Content provided by iHeartPodcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by iHeartPodcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Closing Bell: Tesla Jumps on Robotaxi Rollout, Circle Rises, Hims & Hers Sinks

6:08
 
Share
 

Manage episode 490425420 series 3654950
Content provided by iHeartPodcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by iHeartPodcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

On this episode of Stock Movers:
Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Scarlet Fu, Alix Steel, Carol Massar and Tim Stenovec.
- Tesla (TSLA) shares climbed after the automaker rolled out its long-promised driverless taxi service to a handful of riders, a modest debut for what Elon Musk sees as a transformative new business line. The first robotaxi trips were limited to a narrow portion of Tesla’s hometown of Austin on Sunday, with an employee sitting in the front passenger seat of each vehicle to monitor for safety. The carmaker hand-picked a friendly group of retail investors and social-media influencers to serve as initial riders and live-stream their trips.
- Circle (CRCL) shares extended gains for a third consecutive session after the Senate passed stablecoin legislation last week.
- Hims & Hers (HIMS) shares dropped following news that Novo Nordisk was scrapping a partnership with the upstart telehealth platform after less than two months. Hims, a telehealth platform, wasn’t stepping back enough from its practice of mass marketing off-brand imitations of the weight-loss medicine, Novo executives said.“The big issue with Hims is that we had an agreement that the mass compounding would stop and unfortunately it didn’t stop,” said Ludovic Helfgott, executive vice president of product and portfolio strategy at Novo, in an interview. “That’s why we ended the partnership.” In a post on X, Hims Chief Executive Officer Andrew Dudum called Novo executive comments “misleading.” He said Novo had been pressuring Hims to “steer patients to Wegovy regardless of whether it was clinically best for patients.”

See omnystudio.com/listener for privacy information.

  continue reading

454 episodes

Artwork
iconShare
 
Manage episode 490425420 series 3654950
Content provided by iHeartPodcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by iHeartPodcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

On this episode of Stock Movers:
Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Scarlet Fu, Alix Steel, Carol Massar and Tim Stenovec.
- Tesla (TSLA) shares climbed after the automaker rolled out its long-promised driverless taxi service to a handful of riders, a modest debut for what Elon Musk sees as a transformative new business line. The first robotaxi trips were limited to a narrow portion of Tesla’s hometown of Austin on Sunday, with an employee sitting in the front passenger seat of each vehicle to monitor for safety. The carmaker hand-picked a friendly group of retail investors and social-media influencers to serve as initial riders and live-stream their trips.
- Circle (CRCL) shares extended gains for a third consecutive session after the Senate passed stablecoin legislation last week.
- Hims & Hers (HIMS) shares dropped following news that Novo Nordisk was scrapping a partnership with the upstart telehealth platform after less than two months. Hims, a telehealth platform, wasn’t stepping back enough from its practice of mass marketing off-brand imitations of the weight-loss medicine, Novo executives said.“The big issue with Hims is that we had an agreement that the mass compounding would stop and unfortunately it didn’t stop,” said Ludovic Helfgott, executive vice president of product and portfolio strategy at Novo, in an interview. “That’s why we ended the partnership.” In a post on X, Hims Chief Executive Officer Andrew Dudum called Novo executive comments “misleading.” He said Novo had been pressuring Hims to “steer patients to Wegovy regardless of whether it was clinically best for patients.”

See omnystudio.com/listener for privacy information.

  continue reading

454 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play